BridgeMD
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)
EU CTIS ID: 2023-507889-89-00
What this study is testing
The primary objective of this Platform is, for hospitalized patients with acute respiratory tract infection, to evaluate the effect of a range of interventions on a composite of 90-day all-cause mortality and, among survivors, a daily ordinal scale of trajectory of illness and recovery to 28 days.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Hospitalized patient
- Acute respiratory tract infection
- Aged 28 days or older
- Domain-specific eligibility criteria are met
- The patient is eligible for at least two interventions within a domain
You likely can't join if
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Patient is expected to be discharged from hospital within the next 24 hours
- Previous enrollment in this platform trial within the last 90 days
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.